What cardiac, hepatic, and other clinical evaluations should be performed for a proband with NKX2‑5, NOTCH2, and GDF1 variants of uncertain significance to determine their significance and guide management?

Clinical Evaluation for NKX2-5, NOTCH2, and GDF1 Variants of Uncertain Significance

For a proband with these three VUS, perform comprehensive cardiac phenotyping with ECG, echocardiography, and ambulatory monitoring, along with hepatic evaluation for Alagille syndrome features, recognizing that VUS findings are not clinically actionable until reclassified through clinical correlation and family segregation analysis.

Understanding the Clinical Context

The 2024 AHA/ACC guideline explicitly states that a VUS in a proband is not a clinically actionable result 1. However, clinical phenotyping is essential to potentially reclassify these variants through segregation analysis and clinical correlation. Each gene requires targeted evaluation based on its associated disease spectrum.

Cardiac Evaluation Protocol

For NKX2-5 Variant Assessment

NKX2-5 mutations cause a broad spectrum of cardiac disease with significant morbidity and mortality risk 2, 3. Your evaluation must include:

Structural Assessment:

• Echocardiography to identify:
  • Atrial septal defects (most common association) 4
  • Ventricular septal defects
  • Left ventricular noncompaction 5
  • Dilated cardiomyopathy 3
  • Cardiomyopathy with reduced ejection fraction

Conduction System Evaluation:

• 12-lead ECG looking specifically for:
  • Atrioventricular block (any degree) 6, 5
  • Progressive conduction disease
  • Chronotropic incompetence 6
• 24-48 hour ambulatory ECG monitoring to detect:
  • Intermittent AV block
  • Ventricular arrhythmias (risk of sudden cardiac death) 2, 3
  • Atrial arrhythmias

Functional Assessment:

• Exercise stress testing to evaluate:
  • Chronotropic response 6
  • Exercise-induced arrhythmias 5
  • Syncope risk stratification

Critical Pitfall: NKX2-5 variants associate with sudden cardiac death and lethal arrhythmias 2, 3. Even if the variant remains a VUS, documented conduction disease or cardiomyopathy warrants aggressive monitoring and consideration of device therapy based on phenotype alone.

For GDF1 Variant Assessment

GDF1 has limited but documented association with congenital heart defects. Include:

• Echocardiography for structural heart defects
• Focus on conotruncal and laterality defects

For NOTCH2 Variant Assessment

NOTCH2 is associated with Alagille syndrome, requiring both cardiac and hepatic evaluation:

Cardiac Components:

• Echocardiography focusing on:
  • Peripheral pulmonary stenosis (most common cardiac finding in Alagille)
  • Pulmonary artery hypoplasia
  • Tetralogy of Fallot
  • Other structural defects

Hepatic and Systemic Evaluation

For NOTCH2 (Alagille Syndrome Phenotyping):

• Hepatic function tests: ALT, AST, GGT, bilirubin, alkaline phosphatase
• Coagulation studies: PT/INR (assess synthetic function)
• Lipid panel: cholesterol (often elevated in cholestasis)
• Physical examination for:
  • Jaundice or xanthomas
  • Hepatomegaly
  • Posterior embryotoxon on slit-lamp examination
  • Butterfly vertebrae on spine imaging
  • Characteristic facial features
  • Renal anomalies

Imaging Beyond Echocardiography

Cardiac MRI should be considered if:

• Echocardiography is inconclusive for structural abnormalities 1
• Left ventricular noncompaction is suspected 5
• Cardiomyopathy phenotype needs better characterization
• Sudden cardiac death risk assessment is needed (looking for fibrosis) 1

Surveillance Strategy Based on Guideline Framework

Following the 2024 HCM guideline approach to VUS 1:

If Phenotype is Positive (any cardiac or hepatic abnormality detected):

• The variant gains clinical significance through correlation
• Initiate disease-specific management protocols
• Offer cascade testing to first-degree relatives
• Serial evaluation every 1-2 years with ECG and echocardiography 1
• Ambulatory monitoring every 3-5 years or with symptom changes 1

If Phenotype is Negative:

• VUS remains non-actionable 1
• Consider periodic surveillance given the serious phenotypes associated with these genes:
  • ECG and echocardiography every 2-3 years for young adults
  • Less frequent for older individuals beyond typical disease onset
• Family member testing may be offered at clinical or research level for segregation analysis only with cardiovascular genetics expert guidance 1

Family Segregation Analysis Considerations

Per the 2020 AHA scientific statement 7, if no phenotype is identified in the proband:

• Cascade phenotypic screening of at-risk family members may still be considered
• This depends on the specific gene, variant type, and likelihood of disease relevance
• If family members show phenotypes, genetic testing for the variant helps establish causality through segregation

Critical Distinction: The 2020 guideline notes that when there is no suggestion of disease in the pedigree and the proband has no evidence of disease, family-based evaluations are generally not pursued 7. However, given the serious outcomes associated with NKX2-5 (sudden death, progressive conduction disease) 2, 3, clinical judgment may favor limited family screening even with negative proband phenotype.

Genetic Counseling Requirements

Refer to cardiovascular genetics specialist for:

• Interpretation of VUS in context of clinical findings
• Guidance on family testing strategy
• Discussion of variant reclassification process
• Reproductive counseling if variant is reclassified as pathogenic

Monitoring for Variant Reclassification

Recheck variant classification periodically (annually or biannually), as variants can be downgraded or upgraded based on new evidence 1. If a variant is reclassified:

• From VUS to pathogenic: initiate cascade testing and intensify surveillance
• From VUS to benign: discontinue variant-specific monitoring

Risk Stratification Priority

Given the evidence, NKX2-5 poses the highest mortality risk through sudden cardiac death, progressive conduction disease, and cardiomyopathy 2, 5, 3. Even with VUS status, any phenotypic evidence of NKX2-5-related disease warrants aggressive management including consideration of implantable cardioverter-defibrillator or pacemaker based on clinical criteria 2.